Non-Invasive Markers for Chronic Obstructive Pulmonary Disease (COPD)

Imperial College London1 site in 1 countryJuly 1, 2001

ConditionsHealthy Non-smokers Current Smokers COPD Patients

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Healthy Non-smokers
Sponsor: Imperial College London
Locations: 1
Status: Withdrawn
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary aim of this study is to exploit a difference between COPD patients, chronic smokers without COPD and healthy non-smoking subjects. This will help to assess the utility of inflammatory and oxidative markers in exhaled air and sputum and to compare them with the lung function, clinical parameters and computerised tomography (CT).

Registry

clinicaltrials.gov

Start Date

July 1, 2001

End Date

July 1, 2002

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Imperial College London

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy non-smokers
•FEV1 \>80% predicted
•FEV1 reversibility of \<10% after inhaled (beta2-agonists
•Current smokers
•FEV1 no less than 80% predicted
•FEV1 reversibility of \<10% after inhaled (beta2-agonists
•Smoking history of \> 10 pack-years
•Moderate COPD
•FEV1 40-59% predicted
•FEV1 reversibility of \<10% after inhaled (beta2-agonists

Exclusion Criteria

•FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2-agonists
•unstable disease (FEV1 \<35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection.